Taysha Gene Therapies, Inc. $TSHA is Tybourne Capital Management HK Ltd.’s Largest Position

Tybourne Capital Management HK Ltd. reduced its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 9.6% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,700,000 shares of the company’s stock after selling 395,000 shares during the quarter. Taysha Gene Therapies accounts for about 39.1% of Tybourne Capital Management HK Ltd.’s investment portfolio, making the stock its largest position. Tybourne Capital Management HK Ltd.’s holdings in Taysha Gene Therapies were worth $12,099,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. Marex Group plc bought a new position in shares of Taysha Gene Therapies in the second quarter worth approximately $29,000. E Fund Management Co. Ltd. bought a new stake in Taysha Gene Therapies during the second quarter valued at approximately $31,000. ST Germain D J Co. Inc. grew its stake in Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after buying an additional 4,333 shares in the last quarter. May Hill Capital LLC purchased a new position in Taysha Gene Therapies in the 2nd quarter worth approximately $37,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Taysha Gene Therapies by 156.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after buying an additional 10,742 shares during the last quarter. Institutional investors own 77.70% of the company’s stock.

Insider Transactions at Taysha Gene Therapies

In related news, CEO Sean P. Nolan sold 136,789 shares of Taysha Gene Therapies stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total value of $649,747.75. Following the transaction, the chief executive officer directly owned 2,949,569 shares of the company’s stock, valued at $14,010,452.75. The trade was a 4.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Sukumar Nagendran sold 260,047 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the sale, the insider owned 1,006,439 shares of the company’s stock, valued at $4,539,039.89. This represents a 20.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 968,795 shares of company stock worth $4,518,093. Insiders own 3.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on TSHA. The Goldman Sachs Group set a $11.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. Citizens Jmp upped their price objective on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “market outperform” rating in a report on Wednesday, November 5th. Wells Fargo & Company increased their price objective on Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. Chardan Capital restated a “buy” rating and issued a $12.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $13.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $10.67.

Taysha Gene Therapies Price Performance

TSHA opened at $4.61 on Tuesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. The stock’s 50 day simple moving average is $5.11 and its 200 day simple moving average is $4.21. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of -13.97 and a beta of 1.01. Taysha Gene Therapies, Inc. has a 1 year low of $1.05 and a 1 year high of $6.02.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.